Par reorganizes, drops 190 employees

Par Pharmaceutical will cut 190 jobs--more than a fourth of its workforce--in an effort to contain costs over the next year. Sixty of the 190 workers will see pink slips before they ring in the new year; the rest will be gone by mid- 2009. 

Par's chief operating officer will be leaving the company as well.    

The 20-year-old company will focus on its most profitable products and "align the company's cost structure with the size of its operations and development pipeline," according to the CEO, Pat LePor.  Par execs believe the company's restructuring efforts will result in annual savings of up to $55 million. 

- read the story at LoHud.com
- find the Pharmalot blog post 

 

Suggested Articles

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.

Pfizer's Upjohn has reached a deal to exclusively supply generic Viagra to telehealth provider Roman as the company prepares to merge with Mylan.